SMARCA-BD ligand 1 for Protac is primarily used in targeted protein degradation strategies, specifically in the development of PROTAC (Proteolysis Targeting Chimeras) molecules. Its application lies in binding to the SMARCA2/4 bromodomain, a protein involved in chromatin remodeling and gene regulation. By incorporating this ligand into PROTACs, researchers can selectively degrade SMARCA2/4 proteins, offering a potential therapeutic approach for cancers and other diseases where these proteins are dysregulated. This ligand enables the recruitment of E3 ubiquitin ligases to the target protein, marking it for proteasomal degradation, thus providing a powerful tool for studying protein function and developing novel treatments.